Skip to main content

Table 3 Cause of mortality in patients with IPF treated with antifibrotic therapy

From: Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study

  Switch-IPF (n = 17) Non-Switch-IPF
All cases (n = 130)
Non-Switch-IPF
Continued cases (n = 96)
Non-Switch-IPF
Discontinued cases (n = 34)
Non-Switch IPF versus Switch-IPF
p value
Chronic respiratory failure 9 (52.9%) 74 (56.9%) 55 (57.3%) 19 (55.9%) 0.7988
Acute exacerbation 4 (23.5%) 32 (24.6%) 23 (24.0%) 9 (26.5%) 1.0000
Lung cancer 1 (5.9%) 6 (4.6%) 5 (5.2%) 1 (2.9%) 0.5850
Pneumothorax 0 (0%) 6 (4.6%) 6 (6.3%) 0 (0%) 1.0000
Infection 2 (11.8%) 3 (2.3%) 3 (3.1%) 0 (0%) 0.1024
Others 1 (5.9%) 9 (6.9%) 4 (4.2%) 5 (14.7%) 1.0000